PPAR Research

Research Article

Antioxidant Potential of Adiponectin and Full PPAR-γ Agonist in Correcting Streptozotocin-Induced Vascular Abnormality in Spontaneously Hypertensive Rats

Table 1

Metabolic parameters of WKY, SHR control, and SHR diabetic treated groups with irbesartan, pioglitazone, adiponectin, and a combination of adiponectin with irbesartan or pioglitazone.


Parameters	Groups	Days of observation
Parameters	Groups	Day 0	Day 8	Day 21	Day 28

Body weight (g)	WKY+CNT
	SHR+CNT		^{^}
	SHR+STZ		^{^}	^{^}
	SHR+STZ+Irb
	SHR+STZ+Pio				^ж
	SHR+STZ+Adp
	SHR+STZ+Irb+Adp
	SHR+STZ+Pio+Adp

Water intake (mL/d)	WKY+CNT
	SHR+CNT	^{^}	^!	^!	^!
	SHR+STZ		^{^}	^{^}	^{^}
	SHR+STZ+Irb
	SHR+STZ+Pio
	SHR+STZ+Adp
	SHR+STZ+Irb+Adp
	SHR+STZ+Pio+Adp

UFR (mL/min/100 g)	WKY+CNT
	SHR+CNT	^!	^!	^!	^!
	SHR+STZ		^{^}	^{^}	^{^}
	SHR+STZ+Irb			^{^}	^#
	SHR+STZ+Pio		^δ	^δ	^δж
	SHR+STZ+Adp		^δ	^δ	^δ
	SHR+STZ+Irb+Adp		^δ	^δ	^δΦ
	SHR+STZ+Pio+Adp		^δ	^δ	^δζ

Blood glucose (mg/dL)	WKY+CNT
	SHR+CNT
	SHR+STZ		^{^}	^{^}	^{^}
	SHR+STZ+Irb
	SHR+STZ+Pio
	SHR+STZ+Adp
	SHR+STZ+Irb+Adp
	SHR+STZ+Pio+Adp

Notes: the values are presented as the in each group and were analyzed by repeated measures one-way ANOVA followed by Bonferroni post hoc test. Values with were statistically significant during and at the end of treatment. ! indicates significant difference () between the SHR and WKY control groups. ^ indicates significant difference () between the WKY and SHR control groups in comparison to the SHR diabetic control group. indicates significant difference () in comparison to day 0 of the respective group. δ indicates significant difference () of the diabetic Irb, Pio, Adp, Irb+Adp, and Pio+Adp groups in comparison to the SHR diabetic control group. # indicates significant difference () between the diabetic Irb and Adp groups. ж indicates significant difference () between the diabetic Pio and Adp groups. Φ indicates significant difference () of the diabetic Adp group in comparison to the diabetic Irb+Adp group at days 21 and 28. ζ indicates a significant difference () of the diabetic Adp group in comparison to the diabetic Pio+Adp group at days 21 and 28.